Crohn’s Disease – Professor Thomas Borody Of Australia Comes To New York To Discuss Significant New Findings
There were a total of nine gastroenterologists working across the two tertiary units [RCH and MMC] at the time of the study. Hospital records of all participants were audited, with any vaccinations administered recorded in the outpatient notes and/or a medication chart if administered at the RCH Immunization Drop-in-centre. A telephone interview survey was conducted with consenting parents using the parent-held child immunization record. The vaccination history was checked against the primary care physician and ACIR records. The routine primary childhood vaccinations and administration of the recommended additional influenza and pneumococcal vaccines was clarified. Therapies were categorized into four groups: ASA derivatives (sulphasalazine, osalazine, mesalazine and balsalazide); oral corticosteroids (prednisolone); immunosuppressive agents (azathioprine, methotrexate) and biologics (infliximab). The RCH patient’s hospital laboratory results were reviewed to identify if any baseline serological testing was performed to review the requirement for additional protection against VPD such as varicella and hepatitis B. Multiple sources were reviewed for any vaccine safety concerns or reports of adverse events following immunization, including: hospital records, general practitioner records and parent reports through interviews. A random sample of 101 participants was taken from the IBD register. The random sample was generated using the statistical software STATA Version 10.0 (StataCorp, TX), which was also used for data analysis. This overall sample size calculation was based on the outcome of routine immunization up-to-date status by hospital medical record audit and allowed a determination of proportions within +/- 10% with 95% confidence. Proportions of up-to-date status and additional vaccines administered were compared using a Pearson chi-square test with point estimate odds ratios (OR) and 95% confidence intervals determined and a p value < 0.05 considered statistically significant. The study was approved by the Royal Children's Hospital Human Research Ethics Committee.
anchor text http://www.biomedcentral.com/1471-230X/11/87
Borody’s own patients, to his anti-mycobacteria therapy research. According to Prof. Borody’s report, as many as 95% of his patients have responded to treatment with full remission achieved by 65% of these patients. Dr. Borody says, “These results exceed all documented evidence of response to Crohn’s Disease therapies and promise significant relief for a large number of the estimated one million Crohn’s patients around the world.” Dr. Borody MD PhD FRACP, a graduate of the University of New South Wales, from which he holds a doctorate in medicine, will be presenting his findings in an open forum at: The Suffolk Y Jewish Community Center 74 Hauppauge Road in Commack, Long Island March 20, 2006 from 7-9 PM. Suggested donation $3 As the founder and current Medical Director of the Centre for Digestive Diseases (CDD), Dr. Borody has created a unique medical institution, internationally regarded for its novel approaches in research, diagnosis and the treatment of gastrointestinal conditions. He has been a recipient of the Winthrop Traveling Fellowship, the Neil Hamilton Fairly Fellowship and the Marshall & Warren Prize, and was a Clinical Fellow in Gastroenterology at the Mayo Clinic in Rochester in 1983. He is a member of the Australian Medical Association, the Gastroenterological Society of Australia, the European Gastroenterology Society, the Functional Brain-Gut Research Group and Fellow of the American College of Gastroenterology and the American College of Physicians. Prof. Borody supervises a number of major research programs as well as being involved as a reviewer for the American Journal of Gastroenterology, Digestive Diseases and Sciences, Endoscopy, Journal of Gastroenterology and Hepatology, Medical Journal of Australia and Digestive and Liver Diseases. He has published in excess of 120 scientific papers. In 2004 he was appointed an Adjunct Professor of the Faculty of Science at the University of Technology, Sydney.